Abstract
Seasonal affective disorder is a form of depression that returns at the same time each year, most often in winter, and it can be treated. Guidelines and health services list light therapy, in which a person sits near a bright light box, as a main option. A version of cognitive behavioural therapy adapted for seasonal depression, and some antidepressant medicines, also have research support. Evidence on starting treatment before winter to prevent an episode is limited, and its certainty is mostly very low. Light therapy carries safety cautions for some people, and it is still uncertain how strong and how lasting the benefits of each treatment are.
Keywords: seasonal affective disorder, light therapy, cognitive behavioural therapy, antidepressants, winter depression
Get Help Now
Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.
- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).
This guide describes what published clinical guidelines and research reviews say about treating seasonal affective disorder. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.
How Treatment Is Chosen
The National Institute of Mental Health (NIMH), in the United States, describes both a winter pattern and a summer pattern of seasonal affective disorder (SAD) (National Institute of Mental Health, 2023). NIMH groups SAD treatment into four main categories: light therapy, talking therapy, antidepressant medicine and vitamin D (National Institute of Mental Health, 2023). NIMH notes that no treatments exist specifically for the summer pattern (National Institute of Mental Health, 2023).
The National Health Service (NHS), in the United Kingdom, lists antidepressants, talking therapies and light therapy (National Health Service, 2025). The NHS notes that many people with SAD need treatment each winter to keep symptoms from returning (National Health Service, 2025).
The Canadian Network for Mood and Anxiety Treatments (CANMAT) guideline, from Canada, ranks light therapy as a first-line treatment for depression with a seasonal pattern (Lam et al., 2024). First-line means it is among the first options considered. The guideline adds that most labels describing a depression do little to guide treatment, but a seasonal pattern is one of the few that does (Lam et al., 2024). NIMH advises talking with a health care provider before any change to medicines (National Institute of Mental Health, 2023). A separate guide covers depression treatment more broadly.
Light Therapy
Light therapy means sitting near a light box, a lamp that gives off very bright light (National Institute of Mental Health, 2023). NIMH describes boxes of 10,000 lux, a unit of brightness, used for about 30 to 45 minutes at a time (National Institute of Mental Health, 2023). The Canadian guideline describes 10,000 lux white light for 30 minutes daily (Lam et al., 2024). The NHS notes that light therapy is not usually available through its own services (National Health Service, 2025).
A meta-analysis combines the results of many studies. One from 2020 pooled 19 randomised trials in adults with SAD (Pjrek et al., 2020). Bright light lowered depression scores more than placebo conditions such as dim light (Pjrek et al., 2020). People given bright light were about 1.4 times as likely to respond (Pjrek et al., 2020). Still, the authors rated the risk of bias as moderate to high, and most trials were small to medium in size (Pjrek et al., 2020). An earlier review also found an advantage for bright white light in SAD, but it could assess only short-term effects (Mårtensson et al., 2015). Those authors judged the evidence not clear-cut because of considerable problems in study methods (Mårtensson et al., 2015). Light therapy has also been tested in depression without a seasonal pattern (Perera et al., 2016). Across 20 trials with 881 people, it gave a small to moderate benefit over control conditions (Perera et al., 2016). In the 13 trials that reported response, about 59% responded with light, against 38% in control groups (Perera et al., 2016). However, the authors rated the overall evidence quality as poor, and concluded that light may help people with non-seasonal depression, including as an added treatment (Perera et al., 2016).
Talking Therapy
Cognitive behavioural therapy (CBT) is a structured talking therapy. NIMH describes a version adapted for SAD, called CBT-SAD, given in group sessions over six weeks (National Institute of Mental Health, 2023). It draws on behavioural activation, an approach NIMH also names (National Institute of Mental Health, 2023).
One trial randomly assigned 177 adults with recurrent seasonal depression to six weeks of CBT-SAD or light therapy (Rohan et al., 2015). In that first winter, the two groups improved by similar amounts, with no significant difference (Rohan et al., 2015). On a clinician-rated scale, remission was close to 47% in each group (Rohan et al., 2015). Remission means symptoms fell to a low level. This report was a secondary analysis, and some people left the CBT-SAD group early (Rohan et al., 2015).
The same trial followed people over the next two winters, and in the first of them the two groups did not differ on any outcome (Rohan et al., 2016). By the second winter, depression had returned in 27.3% of the CBT-SAD group, compared with 45.6% of the light therapy group (Rohan et al., 2016). Remission in the second winter, judged on the Beck Depression Inventory, was 68.3% after CBT-SAD and 44.5% after light therapy (Rohan et al., 2016). The authors concluded that the gains from CBT-SAD lasted longer (Rohan et al., 2016). NIMH reports that the two treatments worked equally well, that some symptoms improved slightly faster with light therapy, and that the benefits of CBT-SAD seemed to last longer (National Institute of Mental Health, 2023).
The NHS lists CBT among its talking therapies (National Health Service, 2025). It notes that adults, and in some areas people from age 16, can refer themselves (National Health Service, 2025).
Medicines
NIMH lists selective serotonin reuptake inhibitors (SSRIs) and bupropion as antidepressants used for SAD (National Institute of Mental Health, 2023). According to NIMH, an extended-release form of bupropion is approved by the US Food and Drug Administration (FDA) (National Institute of Mental Health, 2023). NIMH adds that some people may try several medicines before one helps (National Institute of Mental Health, 2023). The NHS also lists antidepressants as a treatment for SAD (National Health Service, 2025).
A Cochrane review looked at second-generation antidepressants for treating an episode of SAD (Nussbaumer-Streit et al., 2021). It found only three small trials, with 204 adults in total (Nussbaumer-Streit et al., 2021). Fluoxetine showed a benefit over placebo that was not significant, and the certainty was very low (Nussbaumer-Streit et al., 2021). Fluoxetine and light therapy gave similar rates of response and remission (Nussbaumer-Streit et al., 2021). Side effects looked similar between groups, but data on them were sparse (Nussbaumer-Streit et al., 2021). The authors judged the evidence too limited for overall conclusions (Nussbaumer-Streit et al., 2021). Another review notes that relatively few studies have tested antidepressants for SAD (Meesters & Gordijn, 2016).
Preventing Winter Episodes
Prevention here means treating adults with past SAD before a new episode begins. A series of four Cochrane reviews has examined it, and three are described here (Nussbaumer-Streit et al., 2019). For light therapy, the review found just one trial, with 46 adults (Nussbaumer-Streit et al., 2019). Fewer people given bright light developed SAD than those given no treatment, but the results were too uncertain to settle the question (Nussbaumer-Streit et al., 2019). The evidence was rated very low quality (Nussbaumer-Streit et al., 2019).
For antidepressants, three trials with 1,100 adults tested an extended-release form of bupropion (Gartlehner et al., 2019). It lowered the risk of a new episode compared with placebo (Gartlehner et al., 2019). Even so, about three in four people taking it did not benefit, and it raised the risk of headache (Gartlehner et al., 2019). All three trials had weaknesses in method, and none compared bupropion with light therapy (Gartlehner et al., 2019).
For talking therapy, one trial of 46 adults tested mindfulness-based cognitive therapy (MBCT) (Forneris et al., 2019). MBCT did not significantly reduce new episodes compared with usual care (Forneris et al., 2019). The evidence was very low quality, so no conclusion could be drawn (Forneris et al., 2019). NIMH also notes that few prevention studies exist (National Institute of Mental Health, 2023).
Safety and Side Effects
One review describes bright light therapy as easy, cheap and well tolerated (Kosanovic Rajacic et al., 2023). Another reports possible side effects such as headaches, nausea, dizziness, restlessness, poor sleep and eye complaints (Meesters & Gordijn, 2016). Very rarely, light therapy has been linked to a swing into hypomania, a period of unusually high mood (Meesters & Gordijn, 2016). A third review notes that, in some cases, hypomania and suicidal thoughts may occur, especially in the first few days of treatment, and it advises monitoring by a health professional (Melrose, 2015).
Light therapy may be unsuitable for people with retinal disease, people who recently had eye surgery, and people taking medicines that increase sensitivity to light (Meesters & Gordijn, 2016). NIMH notes that people with certain eye diseases, or who take certain medicines that increase sensitivity to sunlight, may need other treatments or may need to use light therapy under medical supervision (National Institute of Mental Health, 2023). The NHS advises checking with a GP, or family doctor, before starting light therapy (National Health Service, 2025).
A 2020 meta-analysis studied bright light for depression in bipolar disorder, where a switch into mania is a concern (Takeshima et al., 2020). Across six trials, with 280 people in the analysis, switching to mania was not significantly more common than with control treatment (Takeshima et al., 2020). Overall, bright light did not significantly improve remission, although an analysis limited to the three most directly relevant trials did find a benefit (Takeshima et al., 2020). The trials were few and varied widely, so the authors said the results could not rule out a benefit (Takeshima et al., 2020).
Self-Help and Everyday Measures
The NHS lists self-care measures such as getting daylight, exercising and keeping regular sleep (National Health Service, 2025). It also advises not drinking too much alcohol, not using illegal drugs, and not using electronic devices such as smartphones right before bed (National Health Service, 2025). The NHS suggests seeing a GP if treatment is not helping (National Health Service, 2025).
NIMH lists vitamin D among SAD treatments but describes the evidence as mixed (National Institute of Mental Health, 2023). Some studies found vitamin D about as helpful as light therapy (National Institute of Mental Health, 2023). NIMH warns that vitamin D can interact with other medicines (National Institute of Mental Health, 2023). A 2023 meta-analysis of 41 placebo-controlled trials in adults found that vitamin D supplementation reduced depressive symptoms (Mikola et al., 2023). These trials measured depressive symptoms in general, not SAD alone (Mikola et al., 2023). The certainty was very low, and results varied widely between studies (Mikola et al., 2023).
What Is Still Uncertain
Light therapy beats placebo in pooled SAD trials (Pjrek et al., 2020). One review also reports benefit over placebo across several kinds of depression (Kosanovic Rajacic et al., 2023). Yet the SAD trials are small to medium in size, with moderate to high risk of bias (Pjrek et al., 2020). Results depend heavily on which studies are included, and the review looked only at short-term effects (Mårtensson et al., 2015). For depression without a seasonal pattern, the Canadian guideline notes some heterogeneity among studies, although recent meta-analyses still find light therapy effective (Lam et al., 2024). It also remains to be established who responds best and what timing, frequency and duration of light treatment work best (Kosanovic Rajacic et al., 2023). The NHS states that there is not enough evidence to tell whether light therapy is effective, although many people find it helps (National Health Service, 2025).
Evidence on prevention and medicines is thinner still. The prevention reviews rated the evidence very low quality for both light therapy and MBCT (Nussbaumer-Streit et al., 2019; Forneris et al., 2019). Bupropion did prevent some episodes, but its trials had high dropout rates, and no other antidepressants were studied (Gartlehner et al., 2019). For treating an episode, antidepressant evidence was of low to very low certainty (Nussbaumer-Streit et al., 2021). No trials compared one antidepressant with another or with talking therapy, and the authors called for larger trials (Nussbaumer-Streit et al., 2021).
Learn More
More detail is in the full article on seasonal affective disorder and the guide to depression treatment. There is also a guide to seasonal affective disorder symptoms.
Frequently Asked Questions
What is the main treatment for seasonal affective disorder?
The Canadian CANMAT guideline ranks light therapy as a first line treatment for depression with a seasonal pattern (Lam et al., 2024).
Does light therapy work as well as talking therapy?
In one trial of 177 adults, the SAD version of CBT and light therapy worked about equally well in the first winter (Rohan et al., 2015).
Does the benefit of talking therapy last longer?
By the second winter after treatment, depression had returned in 27.3% of people after the SAD version of CBT, against 45.6% after light therapy (Rohan et al., 2016).
Can an antidepressant prevent a winter episode?
A Cochrane review found that an extended release form of bupropion lowered the risk of a new episode in adults with past SAD, though about three in four people taking it did not benefit (Gartlehner et al., 2019).
Is light therapy safe for people with bipolar disorder?
A meta-analysis of six trials found no significant rise in switching to mania with bright light, and the authors judged it safe over the short periods studied (8 weeks or less), while calling for larger trials (Takeshima et al., 2020).
Does vitamin D help seasonal depression?
NIMH describes the evidence for vitamin D in SAD as mixed (National Institute of Mental Health, 2023).
How This Article Was Prepared
This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests mainly on secondary sources: one clinical guideline, 12 reviews of the research and two pages from public health agencies, with two single studies cited where no review covered the point.
- Included: 17 sources, each confirmed against the publisher's or indexer's own record. Nine read in full text and eight from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 15 references carry a PubMed ID and 11 a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 15 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: nine from the 2010s and eight from 2020 or later. - Checked against sources: each of the 95 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over three passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.
See our Editorial Policy for the full method.
References
Forneris, C. A., Nussbaumer-Streit, B., Morgan, L. C., Greenblatt, A., Van Noord, M. G., Gaynes, B. N., Wipplinger, J., Lux, L. J., Winkler, D., & Gartlehner, G. (2019). Psychological therapies for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews, 5, CD011270. https://doi.org/10.1002/14651858.CD011270.pub3 PMID: 31124141 · PMCID: PMC6533196
Gartlehner, G., Nussbaumer-Streit, B., Gaynes, B. N., Forneris, C. A., Morgan, L. C., Greenblatt, A., Wipplinger, J., Lux, L. J., Van Noord, M. G., & Winkler, D. (2019). Second-generation antidepressants for preventing seasonal affective disorder in adults. Cochrane Database of Systematic Reviews, 3, CD011268. https://doi.org/10.1002/14651858.CD011268.pub3 PMID: 30883669 · PMCID: PMC6422318
Kosanovic Rajacic, B., Sagud, M., Pivac, N., & Begic, D. (2023). Illuminating the way: The role of bright light therapy in the treatment of depression. Expert Review of Neurotherapeutics, 23(12), 1157-1171. https://doi.org/10.1080/14737175.2023.2273396 PMID: 37882458
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., Do, A., Frey, B. N., Giacobbe, P., Gratzer, D., Grigoriadis, S., Habert, J., Husain, M. I., Ismail, Z., McGirr, A., ... Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384 PMID: 38711351 · PMCID: PMC11351064
Meesters, Y., & Gordijn, M. C. M. (2016). Seasonal affective disorder, winter type: Current insights and treatment options. Psychology Research and Behavior Management, 9, 317-327. https://doi.org/10.2147/PRBM.S114906 PMID: 27942239 · PMCID: PMC5138072
Melrose, S. (2015). Seasonal affective disorder: An overview of assessment and treatment approaches. Depression Research and Treatment, 2015, 178564. https://doi.org/10.1155/2015/178564 PMID: 26688752 · PMCID: PMC4673349
Mikola, T., Marx, W., Lane, M. M., Hockey, M., Loughman, A., Rajapolvi, S., Rocks, T., O'Neil, A., Mischoulon, D., Valkonen-Korhonen, M., Lehto, S. M., & Ruusunen, A. (2023). The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition, 63(33), 11784-11801. https://doi.org/10.1080/10408398.2022.2096560 PMID: 35816192
Mårtensson, B., Pettersson, A., Berglund, L., & Ekselius, L. (2015). Bright white light therapy in depression: A critical review of the evidence. Journal of Affective Disorders, 182, 1-7. https://doi.org/10.1016/j.jad.2015.04.013 PMID: 25942575
National Health Service. (2025, December 17). Seasonal affective disorder (SAD). NHS. https://www.nhs.uk/mental-health/conditions/seasonal-affective-disorder-sad/
National Institute of Mental Health. (2023). Seasonal affective disorder (NIH Publication No. 23-MH-8138). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/seasonal-affective-disorder
Nussbaumer-Streit, B., Forneris, C. A., Morgan, L. C., Van Noord, M. G., Gaynes, B. N., Greenblatt, A., Wipplinger, J., Lux, L. J., Winkler, D., & Gartlehner, G. (2019). Light therapy for preventing seasonal affective disorder. Cochrane Database of Systematic Reviews, 2019(3), CD011269. https://doi.org/10.1002/14651858.CD011269.pub3 PMID: 30883670 · PMCID: PMC6422319
Nussbaumer-Streit, B., Thaler, K., Chapman, A., Probst, T., Winkler, D., Sönnichsen, A., Gaynes, B. N., & Gartlehner, G. (2021). Second-generation antidepressants for treatment of seasonal affective disorder. Cochrane Database of Systematic Reviews, 2021(3), CD008591. https://doi.org/10.1002/14651858.CD008591.pub3 PMID: 33661528 · PMCID: PMC8092631
Perera, S., Eisen, R., Bhatt, M., Bhatnagar, N., de Souza, R., Thabane, L., & Samaan, Z. (2016). Light therapy for non-seasonal depression: Systematic review and meta-analysis. BJPsych Open, 2(2), 116-126. https://doi.org/10.1192/bjpo.bp.115.001610 PMID: 27703764 · PMCID: PMC4998929
Pjrek, E., Friedrich, M.-E., Cambioli, L., Dold, M., Jäger, F., Komorowski, A., Lanzenberger, R., Kasper, S., & Winkler, D. (2020). The efficacy of light therapy in the treatment of seasonal affective disorder: A meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 89(1), 17-24. https://doi.org/10.1159/000502891 PMID: 31574513
Rohan, K. J., Mahon, J. N., Evans, M., Ho, S.-Y., Meyerhoff, J., Postolache, T. T., & Vacek, P. M. (2015). Randomized trial of cognitive-behavioral therapy versus light therapy for seasonal affective disorder: Acute outcomes. American Journal of Psychiatry, 172(9), 862-869. https://doi.org/10.1176/appi.ajp.2015.14101293 PMID: 25859764 · PMCID: PMC7962797
Rohan, K. J., Meyerhoff, J., Ho, S.-Y., Evans, M., Postolache, T. T., & Vacek, P. M. (2016). Outcomes one and two winters following cognitive-behavioral therapy or light therapy for seasonal affective disorder. American Journal of Psychiatry, 173(3), 244-251. https://doi.org/10.1176/appi.ajp.2015.15060773 PMID: 26539881 · PMCID: PMC4939843
Takeshima, M., Utsumi, T., Aoki, Y., Wang, Z., Suzuki, M., Okajima, I., Watanabe, N., Watanabe, K., & Takaesu, Y. (2020). Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. Psychiatry and Clinical Neurosciences, 74(4), 247-256. https://doi.org/10.1111/pcn.12976 PMID: 31917880 · PMCID: PMC7187384